BiTEs in myeloma: Why aren’t we talking enough about time limited therapy? 🕰️ Our 69 year old lady with heavily pretreated RRMM received 8 months of teclistamab → CR. Stopped in August 2025 due to recurrent infections. 🙌🏻14 months off therapy: Flow-MRD negative, normal myeloma profile, doing well! ➡️What does emerging evidence show? 🟠LimiTec (n=43): 77% and 73% failure-free probability at 6 and 12 months after stopping teclistamab. 🟠Vega et al., HemaSphere 2026 (n=81): 81% relapse-free at 12 months, 71% at 24 months after bispecific discontinuation; infections prompted discontinuation in 48%. We have stopped bispecifics in 2 more patients, with shorter follow-up. 🛎️Not practice-changing yet, but compelling evidence to investigate finite therapy. Infections, immune suppression, cost and quality of life matter. Should MRD-guided discontinuation be our next frontier in myeloma, rather than indefinite bispecific therapy? #mmsm

Blood cancer treatment is moving beyond conventional chemotherapy. Our conversations with patients need to reflect that. Today, the family of a newly diagnosed myeloma patient came to our OPD. Feared starting “chemo.” Hair loss. Mouth ulcers. Vomiting. That was the picture in their minds. But Dara-VRd works differently. It combines targeted medicines, immune-based treatment and a steroid. It contains no conventional chemotherapy drugs. The side effects they feared are not inevitable. This change extends beyond myeloma: 1. Follicular lymphoma: EHA guidelines out today highlight more chemo-free options, especially at relapse. 2. Ph-positive ALL: new NEJM update of GIMEMA ALL2820 study supports targeted medicine plus immunotherapy, without conventional systemic chemotherapy. These treatments still have risks.Careful monitoring remains essential. Treatment is evolving. The way we explain it should too.

From conversations over dinner to conversations that could change clinical practice! A wonderful pre-conference evening welcoming Dr. Prerna Mewawalla (@myelomadoctor ), myeloma and cellular therapy expert from the USA 🇺🇸, ahead of HemeNext 2.0! 🔥 The weekend promises exciting discussions on evolving #MultipleMyeloma treatment strategies, emerging evidence and their relevance to Indian practice. And there’s more! 🚨 This Sunday, we also mark the launch of #Talquetamab in India, another exciting milestone in the evolving landscape of myeloma therapeutics in India. See you all! #mmsm